Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Nov 01, 2024
Imagine a disease that stealthily incapacitates the heart, liver, and skeletal muscles—slowly breaking them down due to the absence of a crucial protein. That's the story of Pompe disease, also known as glycogen storage disease type II (GSDII). Caused by a gene mutation that blocks the body’s ability to break down ...
Read More...
Oct 16, 2024
Pompe disease is a rare genetic disorder that presents a spectrum of severity, with varying rates of progression and ages of onset. Symptoms can appear anywhere from infancy to late adulthood, with earlier onset generally associated with more rapid progression and increased severity. At all ages, the disease is mar...
Read More...
Sep 30, 2024
The treatment landscape for Pompe disease is undergoing a remarkable shift, especially within emerging markets, as increased awareness, regulatory advancements, and broader access to cutting-edge therapies begin to reshape the future for patients. Pompe disease is a rare and inherited genetic disorder caused by a d...
Read More...
Sep 30, 2024
An orphan disease is any disease that affects only a small percentage of the population. As many as 7,000 rare diseases affect human life. The total number of Americans living with a rare disease is estimated at between 25 and 30 million. In the EU, rare disease patients comprise 6% to 8 % of the population. One...
Read More...
Sep 30, 2024
Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially muscles, impairs their ability to function normally. There are three types of Pompe disease, which differ in severity and the ag...
Read More...
Sep 30, 2024
Pompe disease, an inherited rare disease, is often fatal and incapacitates the heart and skeletal muscles. The absence of an essential protein due to the mutation in a gene encoding GAA, leads to a complex buildup of sugar, hence, damaging the heart, liver, and other organs. The mutated gene hampers the lysosomal-m...
Read More...
Sep 30, 2024
Pompe disease is an inherited rare disease, often fatal, with the potential to damage the heart, liver, and skeletal muscles. Absence of an essential protein, Due to the mutation in a gene encoding GAA, there is an absence of a critical protein leading to a complex buildup of sugar, hence, damaging the heart, liver...
Read More...
Jan 24, 2023
FDA Approves BeiGene’s Brukinsa for CLL/SLL BeiGene's Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has been approved by the US Food and Drug Administration. CLL is a common type of leukemia, accounting for approximately 25% of all new cases each year. SLL is...
Read More...
Dec 20, 2022
AbbVie Secures Fourth FDA Approval for Vraylar AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. According to AbbVie, the approval makes Vraylar (cariprazi...
Read More...
Apr 20, 2022
Drug pricing is one of the hottest topics in the healthcare segment. Several arguments have been put forward by people, governments, healthcare companies, and other organizations in favor of and against expensive medicines. Some of the drugs are so expensive that they are nearly out of reach of the common people. H...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper